Scarica l'app Stockscreener
20.85
1.12%
0.23
Dopo l'orario di chiusura:
20.85
Precedente Chiudi:
$20.62
Aprire:
$20.67
Volume 24 ore:
36,441
Relative Volume:
0.38
Capitalizzazione di mercato:
$486.48M
Reddito:
$36,000
Utile/perdita netta:
$-274.45M
Rapporto P/E:
-1.7654
EPS:
-11.8105
Flusso di cassa netto:
$-150.80M
1 W Prestazione:
+1.21%
1M Prestazione:
-3.87%
6M Prestazione:
+16.61%
1 anno Prestazione:
+150.78%
Intervallo 1D:
$20.20
$21.27
Intervallo di 1 settimana:
$19.59
$21.55
Portata 52W:
$7.65
$45.00
Lyell Immunopharma Inc Stock (LYEL) Company Profile
Nome
Lyell Immunopharma Inc
Settore
Industria
Telefono
650 695-0677
Indirizzo
201 HASKINS WAY, SOUTH SAN FRANCISCO
Compare LYEL vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
20.85 | 481.12M | 36,000 | -274.45M | -150.80M | -11.81 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-10 | Iniziato | Needham | Buy |
| 2026-03-09 | Iniziato | Citizens | Mkt Outperform |
| 2025-12-09 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-10-30 | Downgrade | BofA Securities | Buy → Underperform |
| 2024-06-27 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-08-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-11-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-11 | Downgrade | Goldman | Buy → Neutral |
| 2022-10-17 | Iniziato | H.C. Wainwright | Buy |
| 2021-07-12 | Iniziato | BofA Securities | Buy |
| 2021-07-12 | Iniziato | Goldman | Buy |
| 2021-07-12 | Iniziato | JP Morgan | Overweight |
| 2021-07-12 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Lyell Immunopharma Inc Borsa (LYEL) Ultime notizie
Lyell Immunopharma: Q1 Earnings Snapshot - WKYC
Lyell starts Phase 3 lymphoma dosing, says cash runway reaches Q3 2027 - Stock Titan
Lyell Immunopharma (NASDAQ: LYEL) cuts quarterly loss and raises equity capital - Stock Titan
Lyell Immunopharma (NASDAQ: LYEL) trims Q1 loss and advances CAR T trials - Stock Titan
Lyell Immunopharma (LYEL) Price Target Increased by 27.27% to 14.28 - MSN
LYEL SEC FilingsLyell Immunopharma, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
BofA Securities Maintains Lyell Immunopharma(LYEL.US) With Sell Rating, Maintains Target Price $12 - Moomoo
Lyell Immunopharma (NASDAQ:LYEL) Upgraded by Robert W. Baird to Strong-Buy Rating - MarketBeat
Lyell Immunopharma (NASDAQ:LYEL) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Baird initiates Lyell Immunopharma stock with outperform rating By Investing.com - Investing.com South Africa
Baird initiates Lyell Immunopharma stock with outperform rating - Investing.com
BofA reiterates Lyell Immunopharma stock Underperform on rival exit - Investing.com
BofA reiterates Lyell Immunopharma stock Underperform on rival exit By Investing.com - Investing.com India
Lyell Immunopharma climbs after reporting strong CAR T-cell therapy results - MSN
[ARS] Lyell Immunopharma, Inc. SEC Filing - Stock Titan
Lyell Immunopharma (NASDAQ: LYEL) outlines 2026 virtual meeting, board elections and pay vote - Stock Titan
Lyell Immunopharma (NASDAQ:LYEL) Shares Gap DownHere's What Happened - MarketBeat
LYEL (Lyell Immunopharma Inc.) reports far wider than expected Q4 2025 loss as shares tick modestly higher.Pro Level Trade Signals - Cổng thông tin điện tử tỉnh Tây Ninh
Euler Fund (NASDAQ: LYEL) holds 1,426,528 shares, 6.71% stake disclosed - Stock Titan
Lyell Immunopharma (LYEL) Stock: Gaining Traction? (Underperforming) 2026-04-20Retail Money Flow - Xã Thanh Hà
Lyell Immunopharma (NASDAQ:LYEL) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Sees Large Increase in Short Interest - MarketBeat
LYEL Earnings History & Surprises | EPS & Revenue Results | LYELL IMMUNOPHARMA INC (NASDAQ:LYEL) - ChartMill
A First Look At Lyell Immunopharma (NASDAQ:LYEL) - Seeking Alpha
[EFFECT] Lyell Immunopharma, Inc. SEC Filing - Stock Titan
Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel - The Manila Times
Lyell Immunopharma (NASDAQ:LYEL) Shares Down 4%Should You Sell? - MarketBeat
Lyell Immunopharma (NASDAQ:LYEL) Stock Price Up 6.9%Should You Buy? - MarketBeat
This WhiteFiber Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday - Sahm
Needham initiates coverage of Lyell Immunopharma (LYEL) with buy recommendation - MSN
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Needham & Company LLC Begins Coverage on Lyell Immunopharma (NASDAQ:LYEL) - MarketBeat
Is Lyell Immunopharma (LYEL) Stock Attractive Now | Price at $23.72, Down 0.55%Pro Trader Recommendations - Newser
Lyell Immunopharma (NASDAQ:LYEL) Cut to Strong Sell at Zacks Research - Defense World
Signal Recap: Will Lyell Immunopharma Inc outperform tech stocksQuarterly Performance Summary & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference - Sahm
Lyell Immunopharma to Present at 25th Annual Needham Virtual Healthcare Conference - National Today
Cancer drug developer Lyell will webcast a management presentation Apr. 14 - Stock Titan
Head to Head Analysis: Lyell Immunopharma (NASDAQ:LYEL) & Mangoceuticals (NASDAQ:MGRX) - Defense World
Lyell Immunopharma registers 1.95M shares for resale (NASDAQ: LYEL) - Stock Titan
Lyell Immunopharma (NASDAQ:LYEL) Trading Up 9.2%Time to Buy? - MarketBeat
US Stocks Recap: How sensitive is Lyell Immunopharma Inc to inflation2026 Risk Factors & Reliable Entry Point Alerts - baoquankhu1.vn
Lyell Immunopharma (NASDAQ:LYEL) Lowered to Sell Rating by Wall Street Zen - MarketBeat
LYEL Technical Analysis & Stock Price Forecast - Intellectia AI
Lyell Immunopharma: Strong Early CAR-T Data, And Now A More Measured Bet (NASDAQ:LYEL) - Seeking Alpha
H.C. Wainwright reiterates Lyell Immunopharma stock rating at buy By Investing.com - Investing.com Canada
Is Lyell Immunopharma Inc impacted by rising rates2026 Volume Leaders & Low Volatility Stock Suggestions - baoquankhu1.vn
Lyell Immunopharma (LYEL) grants CFO 140,000 stock options - Stock Titan
Lyell Immunopharma (LYEL) CFO Shah identified as insider in Form 3 - Stock Titan
Lyell Immunopharma, Inc. $LYEL Shares Acquired by Foresite Capital Management V LLC - MarketBeat
Citizens reiterates Lyell Immunopharma stock rating on trial progress By Investing.com - ca.investing.com
Lyell Immunopharma Inc Azioni (LYEL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.77%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):